OnePin Peptide Library · Growth Hormone

Growth Hormone Growth Hormone Secretagogue Blend Not FDA-approved · investigational

CJC-1295 no DAC / GHRP-2 Blend

CJC + GHRP-2

Growth Hormone Secretagogue BlendGHRH + GHRP CombinationSynthetic Hexapeptide + 29-Amino Acid AnalogGhrelin Receptor Agonist + GHRH Receptor Agonist

CJC-1295 no DAC / GHRP-2 Blend is a pre-mixed growth hormone secretagogue combination pairing Modified GRF(1-29) with Growth Hormone Releasing Peptide-2. This dual-action blend stimulates both the GHRH receptor and the ghrelin receptor simultaneously, producing amplified pulsatile GH release that exceeds either peptide alone. It is one of the most widely available GH blends from compounding pharmacies.

Quick Start

Route

Subcutaneous (SubQ) injection

Start low

100mcg CJC / 100mcg GHRP-2 per injection

Frequency

2-3x daily

Timing

Fasted. Minimum 2 hours empty stomach. No eating for 30 min post-injection for optimal GH response.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Quick Start

Conservative start

100mcg CJC / 100mcg GHRP-2 per injection · Subcutaneous (SubQ) injection · 2-3x daily

Lowest starting point. Hold about a week to assess tolerance before stepping up.

100mcg CJC / 100mcg GHRP-2 per injection

2-3x daily

Standard

Standard Synergy

~200 mcg total (100/100) · SubQ · Daily

anecdotal · community

~200 mcg total (100/100)

Daily

Intermediate

Hypertrophy (Twice Daily)

~200 mcg total (100/100) · SubQ · 2x Daily

anecdotal · community

~200 mcg total (100/100)

2x Daily

Reconstitution CalculatorU-100

Vial strength

BAC water

Target dose

050100u

Draw to

— units

◆

How it works

This blend works through dual-receptor stimulation of the GH axis:

CJC-1295 no DAC (Mod GRF 1-29)

Binds GHRH receptors on pituitary somatotrophs, activating cAMP/PKA signaling to prime GH granule release. The four amino acid substitutions protect against DPP-IV degradation while preserving full receptor activity. Without the DAC linker, it produces acute GH pulses with a ~30 minute half-life.

GHRP-2 (Pralmorelin)

Binds GHS-R1a (ghrelin receptor) on the pituitary, triggering GH release through a separate intracellular pathway (PLC/IP3/PKC). Also suppresses somatostatin, removing the natural brake on GH secretion. Stimulates appetite via hypothalamic ghrelin signaling - moderate compared to GHRP-6.

Synergistic Amplification

The GHRH signal (CJC) and GHRP signal (GHRP-2) converge on somatotrophs through independent pathways, producing GH pulses 3-5x greater than either peptide alone. This mimics the natural dual-signal system the body uses for GH regulation.

What to expect

Early

Days 1–7

Days 1-7: Noticeable appetite increase after injection. Improved sleep quality, especially deeper sleep and vivid dreams. Possible mild water retention. Flushing or tingling post-injection is common and harmless.

Mid

Weeks 2–4

Weeks 2-6: Body composition changes becoming visible. Improved skin quality and elasticity. Recovery from training noticeably faster. Fat loss in midsection area. Appetite effect becomes more predictable and manageable.

Later

Weeks 4–12

Weeks 6-12: Full body recomposition effects evident. Lean mass gains consolidated. Skin and hair improvements. Sleep architecture optimized. Consider cycling off after 12 weeks to maintain pituitary sensitivity.

Evidence

HumanModerate

AnimalStrong

In-vitroModerate

1996Growth hormone-releasing peptides: clinical and basic aspects · Bowers CY, Hormone Research ↗review

2005Growth Hormone Releasing Peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men · Laferrere B et al, Journal of Clinical Endocrinology & Metabolism ↗peer reviewed

1997Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature · Mericq V et al, Journal of Endocrinology ↗peer reviewed

2006Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · Teichman SL et al, Journal of Clinical Endocrinology & Metabolism ↗peer reviewed

The honest take

◆

GHRP-2 is approved in Japan as Pralmorelin for clinical use

Partly true

Partially accurate. GHRP-2 (pralmorelin) is approved in Japan specifically as a diagnostic agent for GH deficiency testing, not as a therapeutic drug for GH optimization. The approval confirms safety for single-dose administration.

Moderate appetite stimulation - more than Ipamorelin, less than GHRP-6

Supported

Well-supported by comparative human studies. GHRP-2 produces noticeable but manageable hunger, consistently rated between Ipamorelin (minimal appetite effect) and GHRP-6 (strong hunger drive) in clinical observations.

Cortisol and prolactin elevation is clinically insignificant at standard doses

Dose-dependent. At 100mcg, cortisol and prolactin increases are generally subclinical. Above 200mcg per injection, these elevations become more meaningful. Keeping doses at or below 200mcg GHRP-2 per injection is recommended to minimize this.

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

IpamorelinCan be used at separate times of day. Do not combine two GHRPs in the same injection - use one GHRP per dose.

BPC-157Different mechanism. Can be injected at same time but different site. GH elevation supports BPC repair pathways.

GHK-CuCompatible for tissue repair stacking. GH elevation from blend supports collagen remodeling. Draw GHK-Cu last.

MK-677 (Ibutamoren)Oral GHS-R1a agonist provides sustained baseline GH elevation between injected GHRP-2 pulses. Different pharmacokinetics complement the acute blend pulses.

Keep separate

CJC-1295 with DACDAC version provides continuous GH elevation that disrupts pulsatile signaling. Do not combine sustained and pulsatile GHRH analogs.

Somatostatin analogs (Octreotide)Directly antagonizes GH release. Completely negates the purpose of this blend.

High-dose insulinElevated insulin blunts GH response. Fasted state is required for optimal GH release from this blend.

Side effects & safety

Commonly reported

Moderate appetite increase (15-30 min post-injection, lasts ~1 hour)
Flushing or warmth post-injection (transient, harmless)
Mild water retention in first 1-2 weeks
Tingling or numbness in extremities post-injection
Vivid dreams or disrupted sleep initially

Less common & notes

At higher GHRP-2 doses (above 200mcg), mild cortisol and prolactin elevation may occur.
Symptoms could include slight anxiety or irritability post-injection.
Rarely, mild headache or lethargy.
These effects are dose-dependent and resolve by reducing the GHRP-2 component.
Keep individual GHRP-2 doses at or below 200mcg to minimize these hormonal side effects.

Pharmacokinetics

Illustrative plasma concentration · 24 h

Half-life

CJC-1295 no DAC: ~30 min; GHRP-2: ~25 min. Combined GH pulse duration: 1.5-2 hours.

Peak · Tmax

CJC: 15-30 min; GHRP-2: 15-20 min. Peak synergistic GH release at ~20-30 min post-injection.

Elimination

Both components cleared within 2-3 hours. GH pulse elevation returns to baseline by 3-4 hours.

Activity

GH pulse lasts 1.5-2 hours. Downstream IGF-1 elevation persists 12-20 hours. Appetite effect from GHRP-2 lasts ~1 hour post-injection.

Storage. Store lyophilized vial at room temperature or refrigerated. After reconstitution with bacteriostatic water, store refrigerated at 2-8C. Use within 28-30 days of reconstitution. Do not freeze after reconstitution. Protect from light. Discard if solution becomes cloudy or contains particulate matter.

Regulatory status

Not FDA-approved. Available through compounding pharmacies with prescription. GHRP-2 (pralmorelin) has been studied in clinical trials in Japan and other countries for GH deficiency diagnosis. CJC-1295 no DAC (Mod GRF 1-29) has human pharmacokinetic data. Pre-mixed blends are a compounding pharmacy product. Classified as research peptides in most jurisdictions. All use is experimental/off-label.

Put it to work

Calculate, log & track

Open CJC-1295 no DAC / GHRP-2 Blend straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open CJC-1295 no DAC / GHRP-2 Blend in the app →

Go deeper

The guide & community

The complete CJC-1295 no DAC / GHRP-2 Blend walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community